We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca has announced new medicines and emerging markets have driven its growth in the first half (H1) of 2018. This has been partially offset by the loss of Crestor exclusivity in Europe and Japan.